Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients
Table 5
Characteristics of 29 patients for whom retrospective longitudinal data were available. The group was divided according to changes in eGFR over one-year observation.
Characteristic
Patients with decrease in eGFR ()
Patients without decrease in eGFR ()
value
Age, years
64 ± 15
63 ± 11
0.4
Male sex, (%)
11 (65)
6 (50)
0.4
Known diabetes duration, years
7 (2–11)
10 (4–11)
0.4
HbA1c, %
6.10 (5.70–6.45)
6.20 (5.70–7.00)
0.7
Serum creatinine, μmol/l
61.9 (59.2–72.5)
68.9 (61.4–77.8)
0.5
eGFR (CKD-EPICr), ml/min/1.73 m2
91 (81–98)
96 (80–99)
0.8
Serum cystatin C, mg/l
0.92 (0.82–1.14)
0.86 (0.76–1.10)
0.2
eGFR (CKD-EPICysC), ml/min/1.73 m2
87 (67–96)
96 (70–105)
0.2
Urine albumin, mg/l
8.06 (6.76–13.53)
10.18 (6.21–14.65)
0.9
Urine albumin/creatinine, mg/g
7.93 (3.38–13.38)
8.07 (5.50–16.4)
0.6
Serum NGAL, μg/l
66.7 (49.7–72.3)
44.4 (39.7–55.0)
0.028#
Urine NGAL, μg/l
15.3 (4.0–31.5)
2.9 (1.9–18.5)
0.048#
Urine NGAL/creatinine, μg/g
6.47 (3.36–45.78)
8.82 (2.42–20.3)
0.3
Urine KIM-1, μg/l
1.05 (0.42–1.64)
1.12 (0.35–1.69)
0.9
Urine KIM-1/creatinine, μg/g
1.01 (0.55–1.58)
1.34 (0.59–2.23)
0.5
Urine transferrin, mg/l
<2.17
<2.17
0.1
Detectable urine transferrin (≥2.17 mg/l), (%)
0
2 (17)
0.08
Urine IgG, mg/l
<3.36
<3.36 (<3.36–4.00)
0.2
Detectable urine IgG (≥3.36 mg/l), (%)
2 (12)
4 (33)
0.2
Serum uromodulin, μg/l
125 (97–142)
105 (61–144)
0.5
Urine uromodulin, mg/l
11.30 (6.38–15.50)
4.94 (2.99–14.41)
0.3
Urine uromodulin/creatinine, mg/g
11.20 (6.67–23.17)
10.07 (4.51–15.34)
0.5
#Statistically significant difference between the groups. Abbreviations: see Table 1.
